"[55C1E376CF78]" . . "Treatment of relapsed and refractory Hodgkin lymphoma"@en . . "L\u00E9\u010Dba relabovan\u00E9ho a refraktern\u00EDho Hodgkinova lymfomu"@cs . "M\u00F3cikov\u00E1, Heidi" . . "1"^^ . . "1"^^ . . "CZ - \u010Cesk\u00E1 republika" . "L\u00E9\u010Dba relabovan\u00E9ho a refraktern\u00EDho Hodgkinova lymfomu"@cs . . . "RIV/00064173:_____/10:00002895!RIV13-MZ0-00064173" . "2" . "Hodgkin lymphoma (HL) is usually cured by first-line therapy: in patients in initial stages with unfavorable features relapses occur in 10-15 % of cases and in up to 20 % of patients in advanced stages of HL. The most important prognostic factor at first relapse is chemosensitivity to salvage therapy. No standard salvage regimen is currently recommended, but cisplatinum or carboplatinum based regimens are most widely used. Autologous stem cell transplantation (ASCT) is superior over conventional chemotherapy and remains the standard of treatment in relapsed/refractory Hodgkin lymphoma patients. Tandem transplantation is indicated in poor-risk patients at relapse. ASCT failures occur in approximately 50% of these patients during the follow-up. Experimental approaches after ASCT failure include new agents. The second ASCT is another experimental method. The role of myeloablative allogeneic SCT in multiple relapses of HL is still unclear due to its high treatment-related mortality. Allogeneic transplantation with reduced intensity regimens reduced transplant-related mortality, but even this therapy did not prevent relapses/progressions in about a half or two-thirds of patients."@en . . . . . "V" . "RIV/00064173:_____/10:00002895" . . . "Treatment of relapsed and refractory Hodgkin lymphoma"@en . "16" . "1213-5763" . . "L\u00E9\u010Dba relabovan\u00E9ho a refraktern\u00EDho Hodgkinova lymfomu" . "L\u00E9\u010Dba relabovan\u00E9ho a refraktern\u00EDho Hodgkinova lymfomu" . "7"^^ . . "Relapse; Progression; Hodgkin lymphoma; Autologous stem cell transplantation; Allogeneic stem cell transplantation"@en . "Transfuze a hematologie dnes" . "Hodgkin\u016Fv lymfom (HL) je ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F vyl\u00E9\u010Den prvn\u00ED lini\u00ED terapie. Relapsy se vyskytuj\u00ED u 10-15% pacient\u016F v \u010Dasn\u00FDch stadi\u00EDch s nep\u0159\u00EDzniv\u00FDmi prognostick\u00FDmi faktory a u 20% pacient\u016F s pokro\u010Dil\u00FDm HL. P\u0159i prvn\u00EDm relapsu je nejd\u016Fle\u017Eit\u011Bj\u0161\u00EDm prognostick\u00FDm faktorem odpov\u011B\u010F lymfomu na z\u00E1chrannou l\u00E9\u010Dbu chemosenzitivita). V l\u00E9\u010Db\u011B se nej\u010Dast\u011Bji pou\u017E\u00EDvaj\u00ED re\u017Eimy na b\u00E1zi cisplatiny nebo karboplatiny. Autologn\u00ED transplantace perifern\u00EDch kmenov\u00FDch bun\u011Bk (ASCT) dosahuje lep\u0161\u00EDch v\u00FDsledk\u016F ve srovn\u00E1n\u00ED s konven\u010Dn\u00ED chemoterapi\u00ED a je standardn\u00EDm l\u00E9\u010Debn\u00FDm postupem. Tandemov\u00E1 ASCT je ur\u010Dena pro relabuj\u00EDc\u00ED/refraktern\u00ED pacienty s vysok\u00FDm rizikem selh\u00E1n\u00ED druh\u00E9 linie l\u00E9\u010Dby. P\u0159esto asi u 50% pacient\u016F l\u00E9\u010Dba ASCT selh\u00E1v\u00E1. Standardn\u00ED strategie l\u00E9\u010Dby relapsu po ASCT nen\u00ED jednozna\u010Dn\u011B ur\u010Dena. Experiment\u00E1ln\u011B se zkou\u0161ej\u00ED nov\u00E9 l\u00E9ky. Za experiment\u00E1ln\u00ED postup se pova\u017Euje i druh\u00E1 ASCT. Alogenn\u00ED transplantace s myeloablativn\u00EDm re\u017Eimem u opakovan\u00FDch relaps\u016F HL m\u00E1 vysokou potransplanta\u010Dn\u00ED \u00FAmrtnost. Alogenn\u00ED transplantace u\u017E\u00EDvaj\u00EDc\u00ED re\u017Eimy s redukovanou intenzitou sn\u00ED\u017Eily potransplanta\u010Dn\u00ED \u00FAmrtnost, ale ani tato l\u00E9\u010Dba nezabr\u00E1n\u00ED progresi a/nebo relapsu u poloviny a\u017E 2/3 pacient\u016F." . . "268156" . "Hodgkin\u016Fv lymfom (HL) je ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F vyl\u00E9\u010Den prvn\u00ED lini\u00ED terapie. Relapsy se vyskytuj\u00ED u 10-15% pacient\u016F v \u010Dasn\u00FDch stadi\u00EDch s nep\u0159\u00EDzniv\u00FDmi prognostick\u00FDmi faktory a u 20% pacient\u016F s pokro\u010Dil\u00FDm HL. P\u0159i prvn\u00EDm relapsu je nejd\u016Fle\u017Eit\u011Bj\u0161\u00EDm prognostick\u00FDm faktorem odpov\u011B\u010F lymfomu na z\u00E1chrannou l\u00E9\u010Dbu chemosenzitivita). V l\u00E9\u010Db\u011B se nej\u010Dast\u011Bji pou\u017E\u00EDvaj\u00ED re\u017Eimy na b\u00E1zi cisplatiny nebo karboplatiny. Autologn\u00ED transplantace perifern\u00EDch kmenov\u00FDch bun\u011Bk (ASCT) dosahuje lep\u0161\u00EDch v\u00FDsledk\u016F ve srovn\u00E1n\u00ED s konven\u010Dn\u00ED chemoterapi\u00ED a je standardn\u00EDm l\u00E9\u010Debn\u00FDm postupem. Tandemov\u00E1 ASCT je ur\u010Dena pro relabuj\u00EDc\u00ED/refraktern\u00ED pacienty s vysok\u00FDm rizikem selh\u00E1n\u00ED druh\u00E9 linie l\u00E9\u010Dby. P\u0159esto asi u 50% pacient\u016F l\u00E9\u010Dba ASCT selh\u00E1v\u00E1. Standardn\u00ED strategie l\u00E9\u010Dby relapsu po ASCT nen\u00ED jednozna\u010Dn\u011B ur\u010Dena. Experiment\u00E1ln\u011B se zkou\u0161ej\u00ED nov\u00E9 l\u00E9ky. Za experiment\u00E1ln\u00ED postup se pova\u017Euje i druh\u00E1 ASCT. Alogenn\u00ED transplantace s myeloablativn\u00EDm re\u017Eimem u opakovan\u00FDch relaps\u016F HL m\u00E1 vysokou potransplanta\u010Dn\u00ED \u00FAmrtnost. Alogenn\u00ED transplantace u\u017E\u00EDvaj\u00EDc\u00ED re\u017Eimy s redukovanou intenzitou sn\u00ED\u017Eily potransplanta\u010Dn\u00ED \u00FAmrtnost, ale ani tato l\u00E9\u010Dba nezabr\u00E1n\u00ED progresi a/nebo relapsu u poloviny a\u017E 2/3 pacient\u016F."@cs .